For the past four years, the Neuropathology Core at the Neurosciences and Pathology Departments at UCSD has been operating under the auspices of the NIH Blueprint Neurosciences Core Grant (Stuart Lipton, PI), and is primarily focused at better understanding the mechanisms of synaptic pathology and at developing new experimental therapies for Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), Neurodevelopmental abnormalities, HIV associated dementia (HAD), and other neurodegenerative conditions. This Core Laboratory is headed by Dr. Eliezer Masliah, who has collaborated with a number of neuroscientists on the La Jolla Torrey Pines Mesa and elsewhere for many years, but these facilities had not been previously available to all neuroscientists as a Core until the NIH Blueprint Neuroscience Core Grant was funded. Since the Blueprint Core Grant program is being discontinued by NIH, this NINDS P30 core funding is now requested to continue this core for La Jolla Neuroscientists who are NINDS investigators. Dr. Masliah will continue serve as Director of the Neuropathology Core, which will continue to be located at UCSD. This Core will foster further collaborations and enhance research into neurodegenerative disorders in the San Diego area by NINDS scientists.

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
5P30NS076411-04
Application #
8666084
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Fields, Jerel Adam; Serger, Elisabeth; Campos, Sofia et al. (2016) HIV alters neuronal mitochondrial fission/fusion in the brain during HIV-associated neurocognitive disorders. Neurobiol Dis 86:154-69
Nakanishi, Nobuki; Kang, Yeon-Joo; Tu, Shichun et al. (2016) Differential Effects of Pharmacologic and Genetic Modulation of NMDA Receptor Activity on HIV/gp120-Induced Neuronal Damage in an In Vivo Mouse Model. J Mol Neurosci 58:59-65
Valera, Elvira; Masliah, Eliezer (2016) Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord 31:225-34
Sanz-Blasco, Sara; Piña-Crespo, Juan C; Zhang, Xiaofei et al. (2016) Levetiracetam inhibits oligomeric Aβ-induced glutamate release from human astrocytes. Neuroreport 27:705-9
Nakamura, Tomohiro; Lipton, Stuart A (2016) Nitrosative Stress in the Nervous System: Guidelines for Designing Experimental Strategies to Study Protein S-Nitrosylation. Neurochem Res 41:510-4
Sunico, Carmen R; Sultan, Abdullah; Nakamura, Tomohiro et al. (2016) Role of sulfiredoxin as a peroxiredoxin-2 denitrosylase in human iPSC-derived dopaminergic neurons. Proc Natl Acad Sci U S A 113:E7564-E7571
Valera, E; Monzio Compagnoni, G; Masliah, E (2016) Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy. Neuropathol Appl Neurobiol 42:95-106
Gillman, Alan L; Lee, Joon; Ramachandran, Srinivasan et al. (2016) Small molecule NPT-440-1 inhibits ionic flux through Aβ1-42 pores: Implications for Alzheimer's disease therapeutics. Nanomedicine 12:2331-2340
Akhtar, Mohd Waseem; Sanz-Blasco, Sara; Dolatabadi, Nima et al. (2016) Elevated glucose and oligomeric β-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation. Nat Commun 7:10242
Nakamura, Tomohiro; Prikhodko, Olga A; Pirie, Elaine et al. (2015) Aberrant protein S-nitrosylation contributes to the pathophysiology of neurodegenerative diseases. Neurobiol Dis 84:99-108

Showing the most recent 10 out of 100 publications